Elan Shares Climb on $3.25B Biogen's Tysabri Deal
Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Noble's Battle for Survival After Years of Setbacks
19:43 - Noble Group Ltd. will almost certainly have to undergo a restructuring as the commodity trader battles for survival, according to Muddy Waters LLC founder Carson Block, who’s shorted the company before but says right now he doesn’t have bets against it. Bloomberg's Ruth David takes a look at the growing role of activist investors in Europe. She speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets." (Source: Bloomberg)